Skip to main content
Premium Trial:

Request an Annual Quote

Clontech Licenses CRISPR-Cas9 Technology from Broad Institute

NEW YORK (GenomeWeb) – Clontech Laboratories today announced a non-exclusive licensing deal with the Broad Institute for its CRISPR-Cas9 technology.

The deal provides Clontech, a wholly owned subsidiary of Takara Bio, access to the intellectual property surrounding the technology. The US Patent and Trademark Office granted the Broad the first patent for the CRISPR-Cas9 technology earlier this year.

"We believe that CRISPR-Cas9 technology represents a significant improvement over existing genome editing tools, reaching a new level of targeting, efficiency, and in particular ease of use," Clontech General Manager Carol Lou said in a statement. "It is destined to become as valuable and widely utilized as RNAi — perhaps more so."

Financial and other terms of the deal were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.